Potential role of tocilizumab in severe gastrointestinal barrier damage after CAR T-cell therapy
We report a septicemia and disseminated candidiasis due to delayed gastrointestinal mucosae repair in a patient treated with tocilizumab after anti-CD19 CAR T-cell therapy. Tocilizumab could have inhibited intestinal tissue repair and furthered bacteria translocation leading to the invasion of intes...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-04-01
|
| Series: | Journal of Microbiology, Immunology and Infection |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1684118221000499 |
| id |
doaj-2a65ce551cf44b5f82905d7c384e4549 |
|---|---|
| record_format |
Article |
| spelling |
doaj-2a65ce551cf44b5f82905d7c384e45492021-04-24T05:56:36ZengElsevierJournal of Microbiology, Immunology and Infection1684-11822021-04-01542327330Potential role of tocilizumab in severe gastrointestinal barrier damage after CAR T-cell therapyDavid Beauvais0Oriane Karleskind1Severine Loridant2Remy Nyga3Marie Lamiaux4Anne-Sophie Moreau5Franck Morschhauser6Suman Mitra7Ibrahim Yakoub-Agha8Boualem Sendid9Univ. Lille, CHU Lille, Department of Haematology, F-59000, Lille, France; Corresponding author. UAM allogreffes de Cellules souches hématopoïétiques, CHU Lille F-59037 Lille CEDEX, France. Fax: +33 0 320444094.CHU Lille, Institut de Pathologie, Centre de Biologie Pathologie Génétique, F-59000, Lille, FranceUniv. Lille, Inserm U1285, CNRS UMR 8576 - UGSF - Unité de Glycobiologie Structurale et Fonctionnelle, F-59000 Lille, France; CHU Lille, Service de Parasitologie Mycologie, F-59037 Lille, FranceCHU Lille, Service de Parasitologie Mycologie, F-59037 Lille, FranceCHU Lille, Institut de Pathologie, Centre de Biologie Pathologie Génétique, F-59000, Lille, FranceCHU Lille, Critical Care Centre, F-59000, Lille, FranceUniv. Lille, CHU Lille, Department of Haematology, F-59000, Lille, FranceUniversity of Lille, Inserm, UMR-S 1172, F-59000, Lille, FranceUniv. Lille, CHU Lille, Department of Haematology, F-59000, Lille, France; University of Lille, CHU Lille, Inserm, Infinite, U1286, F-59000 Lille, FranceUniv. Lille, Inserm U1285, CNRS UMR 8576 - UGSF - Unité de Glycobiologie Structurale et Fonctionnelle, F-59000 Lille, France; CHU Lille, Service de Parasitologie Mycologie, F-59037 Lille, FranceWe report a septicemia and disseminated candidiasis due to delayed gastrointestinal mucosae repair in a patient treated with tocilizumab after anti-CD19 CAR T-cell therapy. Tocilizumab could have inhibited intestinal tissue repair and furthered bacteria translocation leading to the invasion of intestinal mucosa by yeasts as IL-6 is known to be involved in mucosal wound healing.http://www.sciencedirect.com/science/article/pii/S1684118221000499CAR T-cellIl-6tocilizumab |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
David Beauvais Oriane Karleskind Severine Loridant Remy Nyga Marie Lamiaux Anne-Sophie Moreau Franck Morschhauser Suman Mitra Ibrahim Yakoub-Agha Boualem Sendid |
| spellingShingle |
David Beauvais Oriane Karleskind Severine Loridant Remy Nyga Marie Lamiaux Anne-Sophie Moreau Franck Morschhauser Suman Mitra Ibrahim Yakoub-Agha Boualem Sendid Potential role of tocilizumab in severe gastrointestinal barrier damage after CAR T-cell therapy Journal of Microbiology, Immunology and Infection CAR T-cell Il-6 tocilizumab |
| author_facet |
David Beauvais Oriane Karleskind Severine Loridant Remy Nyga Marie Lamiaux Anne-Sophie Moreau Franck Morschhauser Suman Mitra Ibrahim Yakoub-Agha Boualem Sendid |
| author_sort |
David Beauvais |
| title |
Potential role of tocilizumab in severe gastrointestinal barrier damage after CAR T-cell therapy |
| title_short |
Potential role of tocilizumab in severe gastrointestinal barrier damage after CAR T-cell therapy |
| title_full |
Potential role of tocilizumab in severe gastrointestinal barrier damage after CAR T-cell therapy |
| title_fullStr |
Potential role of tocilizumab in severe gastrointestinal barrier damage after CAR T-cell therapy |
| title_full_unstemmed |
Potential role of tocilizumab in severe gastrointestinal barrier damage after CAR T-cell therapy |
| title_sort |
potential role of tocilizumab in severe gastrointestinal barrier damage after car t-cell therapy |
| publisher |
Elsevier |
| series |
Journal of Microbiology, Immunology and Infection |
| issn |
1684-1182 |
| publishDate |
2021-04-01 |
| description |
We report a septicemia and disseminated candidiasis due to delayed gastrointestinal mucosae repair in a patient treated with tocilizumab after anti-CD19 CAR T-cell therapy. Tocilizumab could have inhibited intestinal tissue repair and furthered bacteria translocation leading to the invasion of intestinal mucosa by yeasts as IL-6 is known to be involved in mucosal wound healing. |
| topic |
CAR T-cell Il-6 tocilizumab |
| url |
http://www.sciencedirect.com/science/article/pii/S1684118221000499 |
| work_keys_str_mv |
AT davidbeauvais potentialroleoftocilizumabinseveregastrointestinalbarrierdamageaftercartcelltherapy AT orianekarleskind potentialroleoftocilizumabinseveregastrointestinalbarrierdamageaftercartcelltherapy AT severineloridant potentialroleoftocilizumabinseveregastrointestinalbarrierdamageaftercartcelltherapy AT remynyga potentialroleoftocilizumabinseveregastrointestinalbarrierdamageaftercartcelltherapy AT marielamiaux potentialroleoftocilizumabinseveregastrointestinalbarrierdamageaftercartcelltherapy AT annesophiemoreau potentialroleoftocilizumabinseveregastrointestinalbarrierdamageaftercartcelltherapy AT franckmorschhauser potentialroleoftocilizumabinseveregastrointestinalbarrierdamageaftercartcelltherapy AT sumanmitra potentialroleoftocilizumabinseveregastrointestinalbarrierdamageaftercartcelltherapy AT ibrahimyakoubagha potentialroleoftocilizumabinseveregastrointestinalbarrierdamageaftercartcelltherapy AT boualemsendid potentialroleoftocilizumabinseveregastrointestinalbarrierdamageaftercartcelltherapy |
| _version_ |
1721511188396769280 |